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Abstract Methionine adenosyltransferase deficiency
(MAT I/III deficiency) is an inborn error of metabolism
resulting in isolated hypermethioninemia, and usually
inherited as an autosomal recessive trait, although a
dominant form has been reported in several families.
During the last 6 years, approximately 520,000
newborns were screened in the Portuguese Newborn
Screening Laboratory by MS/MS, and 21 cases of
persistent hypermethioninemia were found. One case was
confirmed to be a deficiency of cystathionine b-synthase
and 20 cases were confirmed by MAT1A gene analysis to
have an elevation of methionine due to MAT I/III
deficiency, which indicates an incidence for this condition
of 1/26,000. Twelve of the MAT I/III deficient newborns,
belonging to 11 families, were identified in the northern
region of Portugal and sent to the same treatment center,
where they are under follow-up. Clinical, biochemical, and
genetic characteristics of individuals from these 11 families
are presented. Plasma methionine and homocysteine con-
centrations were found to be moderately increased in all
newborns, and molecular analysis revealed that they all
were heterozygous for R264H mutation. Normal growth,
development, and neurological examination were observed
in all cases, and cerebral MRI performed in six cases
revealed myelination abnormalities in one case. Plasma
methionine concentration for all 12 cases was always below
300 mM, and they are all on a normal diet for their age.
Abbreviations
AdoMet S-adenosylmethionine
CNS Central nervous system
MAT Methionine adenosyltransferase
MRI Magnetic resonance imaging
MS/MS Tandem mass spectrometry
Introduction
Over the last decade, high-throughput methods for multi-
component analyses, especially tandem mass spectrometry
(MS/MS) have transformed newborn population screening.
The overall frequency of disorders detected by MS/MS in
Portugal is about 1 out of every 2,396 (Vilarinho et al.
2010).
Methionine adenosyltransferase deficiency (MAT I/III
deficiency, OMIM 250850) is an inborn error of metabolism
resulting in isolated hypermethioninemia and 1 of the 25
diseases integrated into the panel of the Portuguese National
Newborn Screening Program. This enzyme (MAT, EC
2.5.1.6) catalyzes the biosynthesis of S-adenosylmethionine
from methionine and ATP, and both forms of hepatic MAT
(MAT I and III) are encoded by MAT1A gene (Mudd et al.
2001). In the majority of the cases, MAT I/III deficiency is
inherited as an autosomal recessive trait, although a
dominant form has been reported in several families,
associated with the R264H mutation (Chamberlin et al.
1997; Chou 2000; Chien et al. 2005; Couce et al. 2008).
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Pathogenesis in this disease is not clearly elucidated and
it might result from different factors: extraordinarily high
plasma methionine levels can directly contribute to neuro-
logical abnormalities (Mudd 2011), the lack of synthesis of
S-adenosylmethionine (AdoMet)-dependent methylated
products can cause demyelination (Chamberlin et al.
1996), and hyperhomocysteinemia might bring about an
elevated risk of vascular and thrombotic diseases (Stabler
et al. 2002).
Clinical manifestations in individuals with isolated
persistent hypermethioninemia due to deficient MAT I/III
activity are variable, depending on the extent of the
methionine elevation which, on the other hand, seems to
be related to the specific MAT1A gene mutation (Mudd
2011). In cases associated with R264H mutation, approxi-
mately 30% of residual enzyme activity can be found
(Chamberlin et al. 1997) and in accord with this, clinical
outcome is usually favorable (Pérez Mato et al. 2001).
Nevertheless, caution is recommended regarding the estab-
lishment of genotype/phenotype correlations to predict the
development of CNS problems (Mudd 2011). The optimal
management of MAT I/III deficiency also remains to be
defined, and the clinical and biochemical follow-up of more
patients and during more years is required to achieve
definitive conclusions. Before the introduction, in 2004, of
the MS/MS technology in the Portuguese Newborn Screen-
ing Laboratory, no cases of MAT I/III deficiency were
reported in our population. Since then, 20 newborns and
several related individuals were identified, revealing the
under-diagnosis of this condition in Portugal.
We describe the clinical, biochemical, and genetic
characteristics of 11 families with MAT I/III deficiency,
identified by newborn screening, and who are being
followed in the Oporto Hospital Center. The aims of this
work were: (a) to determine the frequency of hypermethio-
ninemia due to MAT I/III deficiency in the Portuguese
population, (b) to characterize the genotype of affected
individuals and try to establish genotype/phenotype correla-
tions to predict the clinical outcome, and (c) to study the
families in order to identify other individuals at risk.
Patients and Methods
During the last 6 years, approximately 520,000 newborns,
originating from the whole country, were screened in the
Portuguese Newborn Screening Laboratory by MS/MS.
Blood samples were collected between the third and
sixth days of life on Whatman 903 filter paper, and the
analysis of amino acids and acylcarnitines, as butyl esters
(Rashed et al. 1995), was performed using two API
2000 triple quadrupole tandem mass spectrometers. Methi-
onine quantification allows the detection of cystathionine
b-synthase deficiency, as well as hypermethioninemia due
to MAT I/III deficiency. The positive screening criterion
used for both these conditions was a methionine concentra-
tion above 50 mM. The cases of transitory hypermethioni-
nemia were ruled out by asking for a second sample for
confirmation, and only newborns with persistently high
methionine concentrations were sent to a treatment center
for further evaluation; plasma and urinary amino acid
chromatography, plasma total homocysteine, urinary
organic-acid analysis as well as hepatic function evaluation
were performed.
In cases with a persistently high methionine level, MAT
I/III deficiency was confirmed by MAT1A gene analysis.
Genomic DNA was extracted from dried blood spots in
the BioRobot®EZ1, using the EZ1 DNA Tissue Kit from
Qiagen. MAT1A gene exons I–IX and the corresponding
intronic flanking areas were PCR amplified, directly
sequenced using the BigDye Terminator Cycle Sequencing
Version 3.1 from Applied Biosystems and analyzed on an
ABI3130XL DNA Analyzer.
Results
Since 2004, 21 cases of persistent hypermethioninemia
have been confirmed in 520,000 newborns screened in
Portugal. One case was diagnosed as cystathionine beta-
synthase deficiency and 20 cases (14 females and 6 males)
were confirmed to have an isolated elevation of methionine
due to MAT I/III deficiency, which indicates an incidence
for this condition of 1/26,000 newborns. Twelve of these
individuals, belonging to 11 families, were identified in
the northern region of Portugal and sent to the same
treatment center (Table 1). Patients 1–5 were previously
reported (Martins et al. 2007). As far as we could
investigate from family histories, these families are not
related. These patients had methionine concentrations at
screening ranging from 52 to 124 mM (average: 85 mM;
normal < 50 mM). On confirmation (sampling day between
12 days and 1 month), methionine concentration rose in
most patients and ranged from 79 to 247 mM (average:
151 mM; normal < 50 mM). Simultaneously, plasma total
homocysteine was determined and all patients but one were
found to have a mildly increased concentration (range:
13–21 mM; normal < 9 mM). Patient 12 was found to have
a moderate homocysteinemia (64 mM; normal < 9 mM),
and a possible diagnosis of cystathionine b-synthase
deficiency was suspected. While waiting for confirmation,
a low protein diet was immediately started, and after 48 h
homocysteine levels came down to 17 mM. After the
exclusion of this diagnosis, a normal protein diet was
resumed, and total homocysteine concentration never went
again above 20 mM.
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Molecular analysis from the 12 cases revealed that they
all were heterozygous for the R264H mutation, and no
other mutation was identified in the MAT1A gene. The
sequencing of MAT1A exon seven in all patients and their
parents confirmed the association of mutation R264H and
the 870G (rs10887711) and 882C (rs10788546) MAT1A
allelic variants, as previously reported (Chamberlin et al.
1997). The parents of the index cases were studied and, as
expected, one in each family was found to be heterozygous
for the R264H mutation. Parents’ plasma methionine
concentration was also measured (Table 2), and except for
the mother of patients 2 and 3, with normal plasma
methionine, and the mother of patient 12, for whom it
was not possible to measure the methionine, all other
parents with R264H mutation had moderately elevated
methionine concentrations. Except for families of patients
1, 4, and 11, the parents’ methionine concentration was
lower than that of their children on confirmation. For some
of the parents, the plasma total homocysteine levels were
also analyzed and found to be mildly increased. In several
families, methionine was quantified by MS/MS not only in
parents but also in other relatives and those with elevated
methionine levels were all confirmed to be R264H carriers
(Table 2). Except for the father of patient 10, all the other
relatives found to be R264H heterozygotes are clinically
well.
These 12 cases (ages between 1 and 6 years old) are
under biochemical and clinical follow-up in Oporto
Hospital Center and until now all have normal growth,
development, and neurological examination. Cerebral MRI
was performed in the six index cases aged more than
2 years, and only in patient 6 myelination abnormalities
were observed. No other heterozygotes in this family have
neurological signs or symptoms suggestive of myelination
abnormalities.
In families 1 and 4 (from patients 1 and 5), there was a
history of severe vascular disease. In these families, the
mothers both carried the MAT I/III mutation R264H, and
both maternal grandfathers died, at ages 40 and 44 years,
respectively, of thromboembolic events without any other
risk factors being identified. One of these grandfathers
Table 1 Characterization of MAT I/III deficient patients followed in Oporto Hospital Center
Patient Sex Current
age (y/m)
Screening/confirmation
sampling day
Methionine at screening
(normal < 50 mM)
Methionine at confirmation
(normal < 50 mM)
Homocysteine
(normal < 9.0 mM)
1 F 6 y 6/12 85 80 13
2 M 4 y 4/19 77 121 16
3 M 4 y 4/19 52 168 16
4 F 4 y 4/16 103 85 13
5 M 3 y 3/29 58 247 18
6 F 3 y 4/30 80 195 14
7 F 29 m 4/24 85 245 20
8 M 23 m 6/23 73 145 14
9 F 23 m 5/24 124 155 15
10 F 23 m 5/30 91 79 11
11 F 22 m 5/18 117 182 21
12 F 19 m 4/20 79 111 64
m months, y years
Table 2 Characterization of MAT I/III deficient patients’ relatives
Family Patient Affected
relatives
Methionine
(normal <
50 mM)
Homocysteine
(normal <
15.0 mM)
1 1 Mother 114 15.5
2 2, 3 Mother 32 21.9
3 4 Father 119 54.5
4 5 Mother 146 13.9
5 6 Mother 111 ND
Maternal aunt 65 ND
Maternal uncle 112 ND
Maternal
grandmother
92 ND
6 7 Mother 57 ND
7 8 Father 68 ND
Brother 102 ND
8 9 Mother 79 26
9 10 Father 65 28
10 11 Father 187 ND
11 12 Mother ND 30.5
ND not determined
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(family 1) did carry the mutation, but for the other no
mutation analysis was possible. The father of patient 10
also had a myocardial infarction at a young age, but in this
family a history of mild hypercholesterolemia also exists.
Discussion
Screening programs must be adapted to the ethnic and
genetic background, customs, social characteristics, medical
environment, and economic status of a country. Based on
our previous experience in the diagnosis of metabolic
disorders in Portugal, our program includes some diseases
which are prevalent in our population, namely arginase
deficiency, 3-hydroxy-3-methylglutarylCoA lyase defi-
ciency, and cystathionine b-synthase deficiency. Ten cases
of this later disease had been previously diagnosed in our
center, and because of that, methionine measurement was
integrated into our MS/MS screening approach. Unexpect-
edly, during these 6 years of MS/MS screening, only one
case of cystathionine b-synthase deficiency was found and
the predominant cause of hypermethioninemia in Portu-
guese newborns was revealed to be MAT I/III deficiency
(20 out of 21 cases), although no cases were previously
reported in our country.
Most reports of this condition are recent since they are
subsequent to the introduction of the MS/MS technology in
newborn-screening programs. Its true incidence worldwide
is not known, but it is surely under diagnosed (Baric 2009).
The frequency found in our population (1:26,000) is similar
to the one reported in Galicia (Couce et al. 2008), which
may indicate a similar frequency in the whole Iberian
Peninsula.
The molecular study of MAT1A gene allowed the
confirmation of all suspected MAT I/III deficient cases.
Twelve of these cases originate from a small area of Douro
high lands in the northern region of Portugal (Fig. 1), and
all of them were revealed to be heterozygotes for R264H
mutation. Despite the relatively high frequency in the
general population of 870G and 882C MAT1A allelic
variants (58% for both forms in a population of European
ancestry, according to the International HapMap Project
information), the fact that this mutation was found in all
individuals associated with these variants may indicate a
single origin for this allele. At least 37 mutations have so
far been reported in MAT1A gene (Mudd 2011), R264H
exceptionally behaves as a dominant mutation and causes
relatively mild hypermethioninemia, even in heterozygotes.
This behavior is explained by the fact that the R264H
mutated subunit can form inactive dimers with the normal
subunit (Chamberlin et al. 2000; Pérez Mato et al. 2001).
R264H heterozygosity seems to be relatively frequent
among the patients identified by screening for methionine
(Chien et al. 2005; Couce et al. 2008), and it is usually
considered to be clinically benign (Pérez Mato et al. 2001).
The complete lack of MAT I/III activity can represent a risk
for development of brain demyelination, but some residual
activity seems to be sufficient to maintain clinical well-
being (Chamberlin et al. 1996). R264H heterozygotes’
parents and grandparents were found to be generally
healthy, which is in accordance with the residual enzyme
activity reported to be associated with this mutation
(Chamberlin et al. 1997) and which is reflected in the
moderately high methionine levels previously reported for
these individuals (Couce et al. 2008) and confirmed in this
study. Several MAT I/III deficient patients have been
reported who presented with CNS problems, and although
most of them had high plasma methionine levels, certainly
indicating severe MAT I/III deficiencies, genotype/pheno-
type correlations to predict the development of CNS
involvement are still not identified (Mudd 2011). Myelina-
tion alterations do not seem to be directly related to
methionine levels (Chamberlin et al 1996) and can occur
before changes in neurological examination and so, besides
the regular clinical and biochemical monitoring, and in
spite of normal growth, development, and neurological
examination, cerebral MRI was performed in all children
over 2 years old. Before 18 months of age, due to a high
degree of immaturity in myelination, observed alterations
are difficult to evaluate.
The finding of a 3-year-old girl with myelination
abnormalities (patient 6) confirms that care must be taken
when assuming that none of the R264H heterozygote
R264H
Porto
Lisbon
Fig. 1 Hot spot for MAT I/III deficiency due to R264H mutation in a
small area of Douro high lands
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individuals will develop clinical signs. One possibility is
that the observed alterations do not result from the elevated
methionine but from AdoMet depletion, and to confirm this
possibility we intend to perform AdoMet quantification. In
spite of the few experiences reported, and depending on the
individual AdoMet levels observed, AdoMet supplementa-
tion will be considered for all the patients, and especially
for the case presenting brain MRI abnormalities.
Abnormal elevations of plasma total homocysteine have
been reported among more severely affected MAT I/III
deficient patients with the most markedly elevated levels of
plasma methionine (Stabler et al. 2002; Linnebank et al.
2005) and might possibly increase the long-term risk for
strokes (Linnebank et al. 2005). Despite the moderately
increased levels of methionine, all our cases have increased
levels of total homocysteine, and we found two positive
family histories for severe vascular disease episodes
without other risk factors (families 1 and 4). This fact
may indicate that also in cases presenting with moderately
increased plasma methionine and total homocysteine levels,
as are usually the cases associated with R264H mutation,
the risk for vascular diseases may exist. Mild hyper-
homocysteinemia as a risk factor for cardiovascular disease
is a possibility that, although not yet definitely proved,
should still be kept in mind (Smulders and Blom 2011). All
the families are informed regarding the possible risks
associated with R264H heterozygosity. The MAT1A gene
study is offered to all the possible heterozygotes, which are
then advised to do careful regular clinical monitoring.
Since exceptionally high methionine levels were never
observed in our patients, and a low methionine diet can
aggravate AdoMet deficiency and contribute to neurologi-
cal abnormalities (Chien et al. 2005), for the pediatric cases
only regular clinical monitoring and periodical control of
methionine and homocysteine levels are being undertaken.
Conclusion
The neonatal screening community and health care policy
makers have to balance the pros and cons of integrating
some diseases into newborn screening panels. However,
everything that can improve the quality of life of our
children and contribute to the elucidation of the families
should be considered.
The unexpected findings of such a high frequency for
MAT I/III deficiency, and of an hot spot for R264H
mutation in a small region from the north of the country,
brought us new insights into this condition in our country.
A similar high frequency for MAT I/III deficiency due to
R264H was only reported in Galicia, which is not
surprising due to the close historical origins of populations
from Galicia and from the north of Portugal. The long-term
benefit of the screening of this condition will be evaluated
thoroughly.
Synopsis
High frequency of isolated hypermethioninemia detected
in Portuguese newborn screening due to a dominantly
inherited MAT I/III deficiency form associated with R264H
mutation.
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